Content about Pfizer

NEW YORK — An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.

NEW YORK — A Food and Drug Administration expert panel has recommended approval for a drug made by Pfizer for treating rheumatoid arthritis.

NEW YORK — Drug makers could strike big with new treatments for rare diseases, according to a new report by a market research firm.

NEW YORK — Two companies have settled with Teva over the latter's efforts to launch a generic version of an emergency treatment for allergic reactions.

Under the agreement, involving Mylan and Pfizer's Meridian Medical Technologies subsidiary, Teva will be allowed to launch a generic version of EpiPen (epinephrine) auto-injector in June 2015, assuming it wins approval from the Food and Drug Administration. Mylan Specialty markets the EpiPen, which Meridian manufactures.

MADISON, N.J. — As part of a nationwide effort to help communities fight congestion, Pfizer Consumer Healthcare is partnering with the Ohio Association of Police Athletic & Activities League to create more space for the local mentorship program.

The Dayton, Ohio-based mentorship program faces literal congestion, because the facility currently only accommodates 23 students. The expanded room will help 50 additional at-risk area youth get off the waiting list and receive the support they need to stay engaged and motivated after the school day ends.

BOSTON — The Pharmaceutical Research and Manufacturers of America announced Friday the appointment of Eli Lilly chairman, president and CEO John Lechleiter as PhRMA chairman at its annual meeting. The group also elected Celgene president and CEO Robert Hugin as chairman-elect of its board of directors and Pfizer president and CEO Ian Read as board treasurer. Lechleiter replaces Sanofi CEO Christopher Viehbacher as chairman.

NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

PARSIPPANY, N.J. — The U.S. over-the-counter drug market saw strong growth in 2011, thanks to switches of prescription drugs to OTC, gains in the allergy relief products category and holistic marketing, according to a new report from Kline.

According to the international consulting and research firm's Nonprescription Drugs USA 2011 report, at the manufacturers' level, the U.S. OTC drug market posted a gain of 2.4%, reaching $21.4 billion in 2011.

NEW YORK — Pfizer and Indian drug maker Biocon have ended a partnership that the companies started in 2010 to develop biosimilar treatments for diabetes, the companies said.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration is asking for additional data before it approves a new cholesterol drug made by Merck, the drug maker said.

Merck said the agency issued a complete response letter for its regulatory approval application for a drug that would combine the cholesterol drug Zetia (ezetimibe) with atorvastatin, the active ingredient in Pfizer's Lipitor. A complete response letter means that the FDA cannot approve a drug application in its current form.

MUMBAI, India — A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

In a lawsuit filed in the U.S. District Court for the District of New Jersey against Sun Pharmaceutical Industries and Teva Pharmaceutical Industries, Wyeth Pharmaceuticals said it estimated that it suffered damages of $960 million from Sun's and Teva's launches of generic versions of the gastroesophageal reflux disease drug Protonix (pantoprazole).

According to two new surveys of parents and pediatricians from Pfizer Consumer Healthcare, more than half of all parents reported feeling anxious, fearful or helpless when their child comes down with a fever. In addition, many parents are not managing the fever correctly.